Tag Archives: cancer biomarkers market

Cancer Biomarkers Market Size, Trends And Future Forecast Report By Competitor Segment Till 2025

The ****** cancer biomarkers market size was valued at USD 10.27 Billion in 2016 and is expected to reach USD 26.80 Billion in 2025, growing at a CAGR of over 11.35% over the forecast period. Increasing demand for cancer detection techniques and requirement of high-speed non-invasive diagnosis using genomics and proteomics are expected to drive the growth of the market over the forecast period.

Market Outlook:

Cancer Biomarkers: Used for Early Detection of Possible Recurrent Disease

Cancer Biomarkers Industry Report offers detailed analysis of the market over the last five years, and provides extensive market forecasts by region and key players. It covers the key technological and market trends.

Market Definition:

The ****** cancer biomarkers market size was valued at USD 10.27 Billion in 2016 and is expected to reach USD 26.80 Billion in 2025, growing at a CAGR of over 11.35% over the forecast period. Increasing demand for cancer detection techniques and requirement of high-speed noninvasive diagnosis using genomics and proteomics are a few drivers of this market.

Cancer Biomarkers Market: Regional Overview

North America and Europe dominate the ****** cancer biomarkers market on account of high cancer diagnostic and detection procedures, high investment in research and development by pharmaceutical and biotechnology companies and better healthcare infrastructure supporting the R&D activities using biomarkers. Markets in emerging economies such as the Asia Pacific and Latin America are poised to grow at a considerable higher growth rate owing to increasing funding for cancer biomarker research, growing prevalence of cancer, increasing number of clinical trials and growing demand for targeted and personalized drug therapies. The WHO estimates that in 2015 only 35% of the low-income countries reported to have pathology services available in the public sector. The rate is extremely less compared the high-income countries, which reported 90% availability of pathology services. These factors highly govern the growth of cancer biomarkers market, as accessibility would enable uptake of this technology by the users.